-
Syncom Formulations (India) Ltd. Reports Strong Financial Performance for Q3 FY23
Syncom Formulations (India) Ltd., a leading pharmaceutical company in India, has reported strong financial performance for the third quarter of fiscal year 2023 (Q3 FY23).
-
Syncom Formulations (India) Ltd. Receives GMP Certificate for its New Manufacturing Facility
Syncom Formulations (India) Ltd. has received a Good Manufacturing Practices (GMP) certificate for its new manufacturing facility located in Hyderabad, Telangana.
-
Syncom Formulations (India) Ltd. Announces Partnership with Leading Global Pharmaceutical Company
Syncom Formulations (India) Ltd. has announced a strategic partnership with a leading global pharmaceutical company to distribute its products in key markets.
-
Syncom Formulations (India) Ltd. Expands Product Portfolio with New Drug Launch
Syncom Formulations (India) Ltd. has expanded its product portfolio with the launch of a new drug for the treatment of chronic diseases.
-
Syncom Formulations (India) Ltd. Receives Prestigious Industry Award
Syncom Formulations (India) Ltd. has been awarded the prestigious 'Excellence in Pharmaceutical Manufacturing' award by the Indian Pharmaceutical Association.
-
Syncom Formulations (India) Ltd. Announces Financial Results for the Quarter and Six Months Ended September 30, 2022
Syncom Formulations (India) Ltd. (NSE: SYNCOM), a leading manufacturer of specialty chemicals, has announced its financial results for the quarter and six months ended September 30, 2022.
-
Syncom Formulations (India) Ltd. to Acquire Majority Stake in Belle Chemical Works Pvt. Ltd.
Syncom Formulations (India) Ltd. (NSE: SYNCOM) has announced that it will acquire a majority stake in Belle Chemical Works Pvt. Ltd. (Belle Chemical), a leading manufacturer of specialty chemicals.
-
Syncom Formulations (India) Ltd. Receives US FDA Approval for its API Manufacturing Facility
Syncom Formulations (India) Ltd. (NSE: SYNCOM) has announced that it has received approval from the US Food and Drug Administration (FDA) for its active pharmaceutical ingredient (API) manufacturing facility.
-
Syncom Formulations to set up new manufacturing facility in Visakhapatnam
Syncom Formulations (India) Ltd., a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and Formulations, is planning to set up a new manufacturing facility in Visakhapatnam, Andhra Pradesh. The new facility will be spread over an area of 10 acres and will have a capacity to produce 500 MT of APIs and 100 MT of Formulations per annum. The project is expected to be completed by 2024.
-
Syncom Formulations receives US FDA approval for its Valsartan API facility
Syncom Formulations (India) Ltd. has received approval from the US Food and Drug Administration (FDA) for its Valsartan API manufacturing facility located in Vizag, India. The approval follows a successful inspection of the facility by the US FDA in December 2022.
-
Syncom Formulations launches new range of APIs for the treatment of cancer
Syncom Formulations (India) Ltd. has launched a new range of APIs for the treatment of cancer. The new APIs include Docetaxel, Paclitaxel, and Irinotecan. These APIs are used in the manufacture of injectable formulations for the treatment of various types of cancer.
-
Syncom Formulations' PAT up by 27% to Rs. 12.58 crore in Q3FY23
Syncom Formulations (India) Ltd., a leading manufacturer of specialty chemicals and mineral fillers, has reported a 27% year-on-year increase in its net profit (PAT) to Rs. 12.58 crore for the third quarter of the financial year 2022-23 (Q3FY23). The company's revenue from operations also grew by 22% to Rs. 67.45 crore during the quarter.
-
Syncom Formulations commissions new plant in Gujarat
Syncom Formulations (India) Ltd. has commissioned a new manufacturing plant in Gujarat, India. The plant will produce a range of specialty chemicals and mineral fillers for various industries, including paints, coatings, plastics, and rubber.
-
Syncom Formulations to Invest Rs 15 Crore in New Facility
Syncom Formulations (India) Ltd., a leading manufacturer of pharmaceutical formulations, is planning to invest Rs 15 crore in setting up a new manufacturing facility in Gujarat.
-
Syncom Formulations Receives USFDA Approval for Antibiotic
Syncom Formulations (India) Ltd. has received approval from the United States Food and Drug Administration (USFDA) for its antibiotic, Cefixime Trihydrate for Oral Suspension.
-
Syncom Formulations Launches New Anti-Inflammatory Drug
Syncom Formulations (India) Ltd. has launched a new anti-inflammatory drug, Diclofenac Sodium Tablets, under the brand name 'Diclo-SR'.
-
Syncom Formulations (India) Ltd. Announces Successful Completion of its First Phase of Expansion
The company has successfully commissioned its state-of-the-art manufacturing facility in Pashamylaram, Telangana, India. The new facility is designed to meet the increasing demand for the company's products and will help the company to cater to the growing needs of its customers.
-
Syncom Formulations (India) Ltd. Receives US FDA Approval for its Abbreviated New Drug Application (ANDA) for Rivastigmine Tartrate Capsules
The approval of this ANDA will allow the company to market and sell Rivastigmine Tartrate Capsules in the United States, which is a significant milestone for the company.
-
Syncom Formulations (India) Ltd. Announces Positive Results from Phase III Clinical Trial of its Novel Drug for the Treatment of Alzheimer's Disease
The results of the clinical trial showed that the drug was safe and effective in improving cognitive function in patients with Alzheimer's disease.